Compare Crispr Therapeutics AG (CRSP) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs SMX Security Matters plc — how do they compare? Crispr Therapeutics AG trades at $53.37 (market cap $4.88B), while SMX Security Matters plc trades at $3.79 (market cap $4.13M). The key difference: Crispr Therapeutics AG is far larger — about 1181.6× SMX Security Matters plc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and SMX Security Matters plc for 21 Days on average.
| CRSP | SMX | |
|---|---|---|
Market Cap | $4.88B | $4.13M |
Volume | 2,861,747 | 124,362 |
Sector | Health | Industrials |
52-Week High | $74.92 | $74.08K |
52-Week Low | $44.34 | $3.79 |
Typical Hold Time | 77 Days | 21 Days |
Enterprise Value | $3.30B | -$27.20M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
SMX trades at $3.79, down 2.82% with bearish technical signals despite oversold RSI readings. The company shows severe financial distress with zero revenue, negative $169.18M net income, and negative ROE of -819.22%. Recent news highlights SMX's Digital Material Passport technology gaining media attention from Forbes, TIME, and Boston Herald for recycled plastic verification and 'Made in America' authentication solutions.
The outlook remains highly speculative given the absence of revenue and substantial losses. While technology innovation presents long-term potential, immediate risks include cash burn sustainability and dependence on financing activities. Investors should approach with caution given the fundamental weaknesses and bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
